Mast Therapeutics Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Diego CA United States (1995)
Status: Acquired by Savara Inc. (2017)

Organization Overview

First Clinical Trial
1997
NCT00004408
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Mast Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (7)

anx-510 (5 trials)

bevacizumab (avastin) (1 trial)

fluorouracil (efudex) (3 trials)

leucovorin (3 trials)

Poloxalene (2 trials)

sodium chloride (3 trials)

vepoloxamer (5 trials)

Drugs in Phase 2 Trials (2)

Key: Mast Therapeutics (1) Acquired (1)

glucose monohydrate (1 trial)

sodium nitrite (8 trials)

Drugs in Phase 1 Trials (3)

docetaxel (taxotere) (1 trial)

moxifloxacin (avelox) (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 3)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 3)

Cystic Fibrosis (Phase 2)

Fibrosis (Phase 2)

Heart Failure (Phase 2)

Ischemia (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Neoplasms (Phase 1)

Rectal Neoplasms (Phase 2)

Renal Insufficiency (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial APIs: 12